Insider trading

Period: 120 months Stock: CBIO Type of trade: Sold × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

48 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

48 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

48 decisions over 120 months Remove this filter
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

48 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
48 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
48 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

48 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
18 Sep 2026
Brumm Joshua T Chief Executive Officer
Sold on a plan
$130.96K 7,837 at 16.71
2.8%
Planned (10b5-1)
18 Sep 2026
McNeill Jonathan President and COO
Sold on a plan
$64.15K 3,839 at 16.71
2.8%
Planned (10b5-1)
16 Sep 2026
Brumm Joshua T Chief Executive Officer
Sold on a plan
$28.82K 1,610 at 17.90
0.6%
Planned (10b5-1)
16 Sep 2026
McNeill Jonathan President and COO
Sold on a plan
$13.08K 731 at 17.90
0.5%
Planned (10b5-1)
16 Sep 2026
Pinkas Jan Chief Scientific Officer
Sold on a plan
$11.78K 658 at 17.90
3.0%
Planned (10b5-1)
16 Sep 2026
Im Ellie Eunkyung Chief Medical Officer
Sold on a plan
$11.15K 623 at 17.90
2.8%
Planned (10b5-1)
16 Sep 2026
Sold on a plan
$11.10K 620 at 17.90
3.2%
Planned (10b5-1)
16 Sep 2026
Scalzo Richard William Chief Financial Officer
Sold on a plan
$10.17K 568 at 17.90
2.8%
Planned (10b5-1)
16 Sep 2026
Lynch Ryan See Remarks
Sold on a plan
$4.30K 240 at 17.90
1.7%
Planned (10b5-1)
22 Jun 2026
Brumm Joshua T Chief Executive Officer
Sold on a plan
$761.07K 42,305 at 17.99
13.1%
Planned (10b5-1)
22 Jun 2026
McNeill Jonathan President and COO
Sold on a plan
$369.68K 20,549 at 17.99
12.9%
Planned (10b5-1)
22 Jun 2026
Pinkas Jan Chief Scientific Officer
Sold on a plan
$23.17K 1,288 at 17.99
5.5%
Planned (10b5-1)
22 Jun 2026
Im Ellie Eunkyung Chief Medical Officer
Sold on a plan
$21.93K 1,219 at 17.99
5.2%
Planned (10b5-1)
22 Jun 2026
Sold on a plan
$21.91K 1,218 at 17.99
5.9%
Planned (10b5-1)
22 Jun 2026
Scalzo Richard William Chief Financial Officer
Sold on a plan
$20.00K 1,112 at 17.99
5.2%
Planned (10b5-1)
22 Jun 2026
Lynch Ryan See Remarks
Sold on a plan
$8.37K 465 at 17.99
3.2%
Planned (10b5-1)
8 Aug 2024
Sold at will
$50.01K 260,873 at 0.19
4.0%
Not planned
7 Aug 2024
Sold at will
$11.20K 61,488 at 0.18
0.9%
Not planned
6 Aug 2024
Sold at will
$10.19K 55,732 at 0.18
0.8%
Not planned
5 Aug 2024
Sold at will
$31.00K 164,523 at 0.19
2.4%
Not planned
2 Aug 2024
Sold at will
$57.35K 286,200 at 0.20
4.0%
Not planned
1 Aug 2024
Sold at will
$13.74K 63,564 at 0.22
0.9%
Not planned
30 Jul 2024
Sold at will
$167.18K 756,835 at 0.22
9.5%
Not planned
29 Jul 2024
Sold at will
$85.64K 363,949 at 0.24
4.4%
Not planned
26 Jul 2024
Sold at will
$62.44K 258,335 at 0.24
3.0%
Not planned
17 May 2023
Hahn Brian M. SVP Finance, CFO
Sold at will
$7.22K 3,700 at 1.95
6.5%
Not planned
26 Jan 2023
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$9.36M 3,000,000 at 3.12
57.3%
Sold half or more
25 Jan 2023
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$2.13M 652,016 at 3.26
15.4%
5 Jan 2023
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$196.86K 71,362 at 2.76
1.8%
4 Jan 2023
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$296.74K 101,984 at 2.91
2.5%
3 Jan 2023
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$522.71K 174,814 at 2.99
4.2%
30 Dec 2022
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$366.43K 121,335 at 3.02
2.9%
9 Mar 2022
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$3.52K 3,227 at 1.09
1.0%
9 Mar 2022
Hahn Brian M. SVP Finance, CFO
Sold, plan not stated
$3.18K 2,917 at 1.09
7.3%
9 Mar 2022
Girard Armand SVP, Chief Business Officer
Sold, plan not stated
$2.55K 2,339 at 1.09
9.4%
28 Dec 2020
King Rachel K. President, CEO
Sold, plan not stated
$329.13K 84,176 at 3.91
19.1%
18 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$49.45K 3,527 at 14.02
4.4%
17 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$101.82K 7,273 at 14.00
8.4%
16 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$198.94K 14,200 at 14.01
14.1%
11 Jun 2018
Sold, plan not stated
$348.98K 19,345 at 18.04
100%
Sold half or more
10 May 2018
Sold, plan not stated 2×
$169.89K 9,539 at 17.81
0.2%
10 May 2018
BARRETT M JAMES Director · indirect
Sold, plan not stated 2×
$169.89K 9,539 at 17.81
0.2%
10 May 2018
BARRIS PETER J 10% owner · indirect
Sold, plan not stated 2×
$169.89K 9,539 at 17.81
0.2%
10 May 2018
SANDELL SCOTT D 10% owner · indirect
Sold, plan not stated 2×
$169.89K 9,539 at 17.81
0.2%
8 Dec 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$30.02K 2,000 at 15.01
1.3%
18 Sep 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$26.00K 2,000 at 13.00
1.3%
25 May 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$31.14K 2,000 at 15.57
1.3%
19 May 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$24.28K 2,000 at 12.14
1.3%
Showing 1–48 of 48.